Stockscreener 앱 받기
90.24
1.01%
0.90
시간 외 거래:
90.29
0.05
+0.06%
전일 마감가:
$89.34
열려 있는:
$90.56
하루 거래량:
343.81K
Relative Volume:
0.36
시가총액:
$4.91B
수익:
$2.04M
순이익/손실:
$-162.34M
주가수익비율:
-21.94
EPS:
-4.1129
순현금흐름:
$-129.27M
1주 성능:
+7.85%
1개월 성능:
+4.93%
6개월 성능:
+167.54%
1년 성능:
+318.75%
1일 변동 폭
$87.93
$90.90
1주일 범위
$82.00
$91.04
52주 변동 폭
$16.64
$96.50
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
명칭
Dianthus Therapeutics Inc
전화
929-999-4055
주소
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
90.24 | 4.86B | 2.04M | -162.34M | -129.27M | -4.1129 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-09 | 개시 | Wolfe Research | Outperform |
| 2026-03-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-10-14 | 개시 | Truist | Buy |
| 2025-07-02 | 개시 | William Blair | Outperform |
| 2024-12-20 | 개시 | TD Cowen | Buy |
| 2024-10-03 | 개시 | Oppenheimer | Outperform |
| 2024-07-26 | 개시 | Robert W. Baird | Outperform |
| 2024-06-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-16 | 개시 | H.C. Wainwright | Buy |
| 2024-02-15 | 개시 | Stifel | Buy |
| 2023-12-26 | 개시 | Jefferies | Buy |
| 2023-11-22 | 개시 | Wedbush | Outperform |
| 2023-10-30 | 개시 | Guggenheim | Buy |
| 2023-09-28 | 개시 | Raymond James | Outperform |
| 2022-08-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-01-06 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-08-20 | 재개 | Goldman | Neutral |
| 2021-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-07-22 | 재확인 | B. Riley Securities | Buy |
| 2021-06-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-05-18 | 개시 | B. Riley Securities | Buy |
| 2021-01-07 | 개시 | Mizuho | Buy |
| 2020-06-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-03-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-03-15 | 개시 | Raymond James | Outperform |
모두보기
Dianthus Therapeutics Inc 주식(DNTH)의 최신 뉴스
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis - GlobeNewswire Inc.
Dianthus Therapeutics (NASDAQ:DNTH) Releases Earnings Results, Beats Expectations By $0.25 EPS - MarketBeat
Dianthus Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Earnings Flash (DNTH) Dianthus Therapeutics, Inc. Reports Q1 Revenue $463K, vs. FactSet Est of $404K - marketscreener.com
Dianthus Therapeutics (NASDAQ: DNTH) builds $1.1B cash to fund autoimmune pipeline - Stock Titan
Dianthus got 20 responders before 40 patients in CIDP trial - Stock Titan
Dianthus (Nasdaq: DNTH) raises $719M, ends Q1 2026 with $1.2B cash - Stock Titan
Dianthus Therapeutics (DNTH) to Release Earnings on Monday - MarketBeat
MSN Money - MSN
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Six new Dianthus hires get options to buy 135,000 shares - Stock Titan
Dianthus Therapeutics (DNTH) price target increased by 70.00% to 130.48 - MSN
Short Interest in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Decreases By 27.6% - MarketBeat
Assessing Dianthus Therapeutics (DNTH) Valuation After FDA Trial Shift And Renewed Analyst Optimism - Yahoo Finance
BlackRock holds 2.63M Dianthus shares (NASDAQ: DNTH) — 5.1% stake - Stock Titan
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
Does Dianthus Therapeutics (DNTH) Trial Easing Quietly Redefine Its Long-Term Neuromuscular Strategy? - Sahm
Certain Stock Options of Dianthus Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2026. - marketscreener.com
Dianthus Therapeutics announces proposed $400 million public share offering - MSN
Dianthus rises as FDA agrees with proposed changes to lead program - MSN
Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier - Insider Monkey
5 Best 52-Week High US Stocks to Buy - Insider Monkey
Dianthus (DNTH) Investment Thesis | Dianthus Therapeutics Inc posts 30.3% EPS miss with no revenueHedge Fund Inspired Picks - Cổng thông tin điện tử Tỉnh Sơn La
Dianthus Therapeutics CFO Sells All Shares in 2026 Transaction | Company UpdateNews and Statistics - IndexBox
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000 - AOL.com
Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target - MSN
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: Exploring a 35% Upside Potential Amid Biotech Innovations - DirectorsTalk Interviews
Dianthus Therapeutics (DNTH) Is Up 10.1% After $719M Raise And Insider Sale Has The Bull Case Changed? - Sahm
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Dianthus Therapeutics CFO Sells $9.5 Million in Stock - AOL.com
Dianthus Therapeutics shares jump 25% after encouraging clinical trial update - MSN
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year HighShould You Buy? - MarketBeat
Dianthus Therapeutics EVP Sells $10M in Shares - National Today
SG Americas Securities LLC Invests $765,000 in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
DNTH SEC FilingsDianthus Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Dianthus Therapeutics (NASDAQ:DNTH) EVP Ryan Savitz Sells 8,224 Shares - MarketBeat
Ryan Savitz, Dianthus Therapeutics CFO, sells $738k in DNTH stock - Investing.com Canada
Dianthus Therapeutics Insider Sold Shares Worth $738,844, According to a Recent SEC Filing - marketscreener.com
Dianthus (NASDAQ: DNTH) CFO exercises options, sells 8,224 shares under 10b5-1 plan - Stock Titan
Dianthus Therapeutics Upgraded to Strong Buy at Wolfe Research - National Today
Dianthus Therapeutics (NASDAQ:DNTH) Upgraded by Wolfe Research to "Strong-Buy" Rating - MarketBeat
Dianthus Therapeutics Inc (DNTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):